Quantcast

Latest Attention-deficit hyperactivity disorder management Stories

2009-09-09 08:59:18

Low levels of dopamine markers may underlie symptoms; implications for treatment.

2009-09-09 07:00:00

TITUSVILLE, N.J., Sept. 9 /PRNewswire/ -- Attention Deficit Hyperactivity Disorder (ADHD) is estimated to impact up to 20 percent of children(1) and 4 percent of adults in the U.S.(2) Recent studies suggest ADHD is underdiagnosed: researchers estimate up to 20 percent of U.S.

2009-09-03 07:00:00

PHILADELPHIA, September 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.

2009-08-21 15:04:29

Parents should be aware of certain behavioral symptoms in the classroom that might indicate their child should be screened for attention deficit disorder and attention deficit hyperactivity disorder, an expert at Baylor College of Medicine

2009-08-17 13:43:33

Language is a central element of social life. It is not only a prerequisite for personal relationships, but also for employment prospects. If a child's language development is impaired

2009-08-17 08:00:00

PHILADELPHIA, Aug.

2009-07-28 01:00:00

PHILADELPHIA, July 28 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date. The FDA did not identify safety concerns regarding INTUNIV in the Complete...

2009-07-22 17:15:00

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder

2009-07-22 08:00:00

PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse(R)( )(lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last...


Word of the Day
begunk
  • To befool; deceive; balk; jilt.
  • An illusion; a trick; a cheat.
The word 'begunk' may come from a nasalised variant of Scots begeck ("to deceive, disappoint"), equivalent to be- +‎ geck.